Cardiovascular risk in menopausal women and prevalent related co-morbid conditions: facing the post-Women's Health Initiative era

Fertility and Sterility

Volumn 92, Issue 4, 2009, Pages 1171-1186

  Pérez López, Faustino R ^a   Chedraui, Peter ^b   Gilbert, Juan J ^b   Pérez Roncero, Gonzalo ^c  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b UNIVERSIDAD CATÓLICA DE SANTIAGO DE GUAYAQUIL   (Ecuador)

^c Instituto Ginecológico de Zaragoza   (Spain)

Author keywords

cardiovascular disease; depression; hormone therapy; Menopause; obesity; psychosocial factors; sleeping disorders; vitamin D insufficiency

Indexed keywords

CARDIOVASCULAR RISK; COMORBIDITY; DEPRESSION; DYSLIPIDEMIA; FEMALE; HORMONAL THERAPY; HUMAN; HYPERTENSION; LIFESTYLE; MEDLINE; MENOPAUSE; METABOLIC SYNDROME X; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SEXUAL DYSFUNCTION; SLEEP DISORDER; SOCIAL PSYCHOLOGY; STRESS; VITAMIN D DEFICIENCY;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; COMORBIDITY; CROSS-SECTIONAL STUDIES; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; RISK FACTORS; WOMEN'S HEALTH;

EID: 70349607263     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.06.032     Document Type: Review

References (158)

1. Naftolin F., Taylor H.S., Karas R., Brinton E., Newman I., Clarkson T.B., et al. Women's Health Initiative. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 81 (2004) 1498-1501
2. Anderson R.N., Kochanek K.D., and Murphy S.L. Report of final mortality statistics, 1995. Monthly vital statistics report, Vol. 45, No. 11, Suppl 2 (1997), National Center for Health Statistics, Hyattsville, MD 22-23
3. Stevenson J.C. HRT and the primary prevention of cardiovascular disease. Maturitas 57 (2007) 31-34
4. International Clinical Epidemiology Network. Body mass index and cardiovascular disease risk factors in seven Asian and five Latin American centers: data from the International Clinical Epidemiology Network (INCLEN). Obes Res 4 (1996) 221-228
5. Liu P.Y., Death A.K., and Handelsman D.J. Androgens and cardiovascular disease. Endocrinol Rev 24 (2003) 313-340
6. Pearls T. Why do women outlive men? Available at:. http://sonibyte.com/audio/7528.mp3 Last accessed on August 11, 2008
7. The Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principles results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
8. Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
9. Lobo R.A. Metabolic syndrome after menopause and the role of hormones. Maturitas 60 (2008) 10-18
10. Turgeon J.L., Carr M.C., Maki P.M., Mendelsohn M.E., and Wise P.M. Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: insights from basic science and clinical studies. Endocrinol Rev 27 (2006) 575-605
11. Subah Packer C. Estrogen protection, oxidized LDL, endothelial dysfunction and vasorelaxation in cardiovascular disease: new insights into a complex issue. Cardiovasc Res 73 (2007) 6-7
12. Fadini G.P., de Kreutzenberg S., Albiero M., Coracina A., Pagnin E., Baesso I., et al. Gender differences in endothelial progenitor cells and cardiovascular risk profile: the role of female estrogens. Arterioscler Thromb Vasc Biol 28 (2008) 997-1004
13. Christian R.C., Liu P.Y., Harrington S., Ruan M., Miller V.M., and Fitzpatrick L.A. Intimal estrogen receptor (ER) beta, but not ER alpha expression, is correlated with coronary calcification and atherosclerosis in pre- and postmenopausal women. J Clin Endocrinol Metab 91 (2006) 2713-2720
14. Haas E., Meyer M.R., Schurr U., Bhattacharya I., Minotti R., Nguyen H.H., et al. Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension 49 (2007) 1358-1363
15. Kublickiene K., Svedas E., Landgren B.M., Crisby M., Nahar N., Nisell H., et al. Small artery endothelial dysfunction in postmenopausal women: in vitro function, morphology, and modification by estrogen and selective estrogen receptor modulators. J Clin Endocrinol Metab 90 (2005) 6113-6122
16. Arnal J.F., Douin-Echinard V., Brouchet L., Tremollières F., Laurell H., Lenfant F., et al. Understanding the oestrogen action in experimental and clinical atherosclerosis. Fundam Clin Pharmacol 20 (2006) 539-548
17. Barton M., Cremer J., and Mügge A. 17Beta-estradiol acutely improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries. Eur J Pharmacol 362 (1998) 73-76
18. Lewis D.A., Avsar M., Labreche P., Bracamonte M., Jayachandran M., and Miller V.M. Treatment with raloxifene and 17beta-estradiol differentially modulates nitric oxide and prostanoids in venous endothelium and platelets of ovariectomized pigs. J Cardiovasc Pharmacol 48 (2006) 231-238
19. Ling S., Zhou L., Li H., Dai A., Liu J.P., Komesaroff P.A., et al. Effects of 17beta-estradiol on growth and apoptosis in human vascular endothelial cells: influence of mechanical strain and tumor necrosis factor-alpha. Steroids 71 (2006) 799-808
20. Mori M., Tsukahara F., Yoshioka T., Irie K., and Ohta H. Suppression by 17beta-estradiol of monocyte adhesion to vascular endothelial cells is mediated by estrogen receptors. Life Sci 75 (2004) 599-609
21. Sumino H., Ichikawa S., Ohyama Y., Takahashi T., Saito Y., Nakamura T., et al. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women. Am J Cardiol 96 (2005) 148-153
22. Stumpf C., John S., Jukic J., Yilmaz A., Raaz D., Schmieder R.E., et al. Enhanced levels of platelet P-selectin and circulating cytokines in young patients with mild arterial hypertension. J Hypertens 23 (2005) 995-1000
23. Sesso H.D., Buring J.E., Rifai N., Blake G.J., Gaziano J.M., and Ridker P.M. C-reactive protein and the risk of developing hypertension. JAMA 290 (2003) 2945-2951
24. Piché M.E., Lemieux S., Weisnagel S.J., Corneau L., Nadeau A., and Bergeron J. Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women. Am J Cardiol 96 (2005) 92-97
25. Piconi S., Trabattoni D., Luraghi C., Perilli E., Borelli M., Pacei M., et al. Treatment of periodontal disease results in improvements in endothelial dysfunction and reduction of the carotid intima-media thickness. FASEB J 23 (2009) 1196-1204
26. Burke A.P., Farb A., Malcom G., and Virmani R. Effect of menopause on plaque morphologic characteristics in coronary atherosclerosis. Am Heart J 141 (2001) S58-S62
27. Akçay Y.D., Sagin F.G., Sendaǧ F., Oztekin K., and Sozmen E.Y. Effects of estrogen-only therapy on LDL oxidation in women with hysterectomy: does paraoxonase genotype play a role?. Maturitas 53 (2006) 325-332
28. Krasinski K., Spyridopoulos I., Asahara T., van der Zee R., Isner J.M., and Losordo D.W. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 95 (1997) 1768-1772
29. Duckles S.P., Krause D.N., Stirone C., and Procaccio V. Estrogen and mitochondria: a new paradigm for vascular protection?. Mol Interv 6 (2006) 26-35
30. Simoncini T., Mannella P., Fornari L., Caruso A., Willis M.Y., Garibaldi S., et al. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 145 (2004) 5745-5756
31. Jeanes H.L., Wanikiat P., Sharif I., and Gray G.A. Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia-reperfusion injury. Menopause 13 (2006) 80-86
32. Pérez-López F.R. Clinical experiences with drospirenone: from reproductive to postmenopausal years. Maturitas 60 (2008) 78-91
33. Nathan L., Shi W., Dinh H., Mukherjee T.K., Wang X., Lusis A.J., et al. Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci USA 98 (2001) 3589-3593
34. Davison S.L., Bell R., Donath S., Montalto J.G., and Davis S.R. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 90 (2005) 3847-3853
35. Bell R.J., Davison S.L., Papalia M.A., McKenzie D.P., and Davis S.R. Endogenous androgen levels and cardiovascular risk profile in women across the adult life span. Menopause 14 (2007) 630-638
36. Maturana M.A., Breda V., Lhullier F., and Spritzer P.M. Relationship between endogenous testosterone and cardiovascular risk in early postmenopausal women. Metabolism 57 (2008) 961-965
37. Lambrinoudaki I., Christodoulakos G., Rizos D., Economou E., Argeitis J., Vlachou S., et al. Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women. Eur J Endocrinol 154 (2006) 907-916
38. Barrett-Connor E.L., and Goodman-Gruen D. Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. Br Med J 311 (1995) 1193-1196
39. Goodman-Gruen D., and Barrett-Connor E. A prospective study of sex hormone-binding globulin and fatal cardiovascular disease in Rancho Bernardo men and women. J Clin Endocrinol Metab 81 (1996) 2999-3003
40. Bernini G.P., Sgro M., Moretti A., Argenio G.F., Barlascini C.O., Cristofani R., et al. Endogenous androgens and carotid intimal-medial thickness in women. J Clin Endocrinol Metab 84 (1999) 2008-2012
41. Golden S.H., Maguire A., Ding J., Crouse J.R., Cauley J.A., Zacur H., et al. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. Am J Epidemiol 155 (2002) 437-445
42. Debing E., Peeters E., Duquet W., Poppe K., Velkeniers B., and Van den Brande P. Endogenous sex hormone levels in postmenopausal women undergoing carotid artery endarterectomy. Eur J Endocrinol 156 (2007) 687-693
43. Anderson G.L., Limacher M., Assaf A.R., Bassford T., Beresford S.A., Black H., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
44. Hsia J., Langer R.D., Manson J.E., Kuller L., Johnson K.C., Hendrix S.L., et al., Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Arch Intern Med 166 (2006) 357-365
45. Rossouw J.E., Prentice R.L., Manson J.E., Wu L., Barad D., Barnabei V.M., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297 (2007) 1465-1477
46. Allison M.A., Manson J.E., Langer R.D., Carr J.J., Rossouw J.E., Pettinger M.B., et al., Women's Health Initiative and Women's Health Initiative Coronary Artery Calcium Study Investigators. Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women's Health Initiative coronary artery calcium study. Menopause 15 (2008) 639-647
47. Vickers M.R., MacLennan A.H., Lawton B., Ford D., Martin J., Meredith S.K., et al. WISDOM group. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 335 (2007) 239
48. Tannen R.L., Weiner M.G., Xie D., and Barnhart K. Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy. Hum Reprod 22 (2007) 1769-1777
49. Howard B.V., Kuller L., Langer R., Manson J.E., Allen C., Assaf A., et al. Women's Health Initiative. Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women's Health Initiative Observational Study. Circulation 111 (2005) 1462-1470
50. Kanaya A.M., Herrington D., Vittinghoff E., Lin F., Grady D., Bittner V., et al. Heart and Estrogen/progestin Replacement Study. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 138 (2003) 1-9
51. Kernohan A.F., Sattar N., Hilditch T., Cleland S.J., Small M., Lumsden M.A., et al. Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes. Clin Endocrinol (Oxf) 66 (2007) 27-34
52. Wu O. Postmenopausal hormone replacement therapy and venous thromboembolism. Gend Med 2 (2005) S18-S27
53. Canonico M., Oger E., Plu-Bureau G., Conard J., Meyer G., Lévesque H., et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115 (2007) 840-845
54. Canonico M., Plu-Bureau G., Lowe G.D.O., and Scarabin P.Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 336 (2008) 1227-1231
55. Hemelaar M., van der Mooren M.J., Rad M., Kluft C., and Kenemans P. Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. Fertil Steril 90 (2008) 642-672
56. Salpeter S.R., Walsh J.M., Ormiston T.M., Greyber E., Buckley N.S., and Salpeter E.E. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 8 (2006) 538-554
57. Sare G.M., Gray L.J., and Bath P.M.W. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 29 (2008) 2031-2041
58. Grodstein F., Manson J.E., Stampfer M.J., and Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 28 (2008) 168:861-6
59. Marrugat J., Solanas P., D'Agostino R., Sullivan L., Ordovás J., Cordón F., et al. Coronary risk estimation in Spain using a calibrated Framingham function. Rev Esp Cardiol 56 (2003) 253-261
60. Izumi Y., Matsumoto K., Ozawa Y., Kasamaki Y., Shinndo A., Ohta M., et al. Effect of age at menopause on blood pressure in postmenopausal women. Am J Hypertens 20 (2007) 1045-1050
61. Lewington S., Clarke R., Qizilbash N., Peto R., and Collins R. Age-specific relevance of usual blood pressure to vascular mortality. Lancet 360 (2002) 1903-1913
62. Khatibi A., Agardh C.D., Nyberg P., Lidfeldt J., and Samsioe G. Blood pressure in middle-aged women: are androgens involved? A population-based study of Swedish women: the Women's Health in the Lund Area study. J Hypertens 25 (2007) 2044-2050
63. Mirza F.S., Ong P., Collins P., Okamura K., Gerhard-Herman M., Williams G.H., et al. Effects of estradiol and the angiotensin II receptor blocker irbesartan on vascular function in postmenopausal women. Menopause 15 (2008) 44-50
64. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
65. Hsia J., Margolis K.L., Eaton C.B., Wenger N.K., Allison M., Wu L., et al. Women's Health Initiative Investigators. Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation 115 (2007) 855-860
66. Gerber L.M., Sievert L.L., Warren K., Pickering T.G., and Schwartz J.E. Hot flashes are associated with increased ambulatory systolic blood pressure. Menopause 14 (2007) 308-315
67. Gast G.C., Grobbee D.E., Pop V.J., Keyzer J.J., Wijnands-van Gent C.J., Samsioe G.N., et al. Menopausal complaints are associated with cardiovascular risk factors. Hypertension 51 (2008) 1492-1498
68. Preston R.A., Norris P.M., Alonso A.B., Ni P., Hanes V., and Karara A.H. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. Menopause 14 (2007) 408-414
69. Karelis A.D., Pasternyk S.M., Messier L., St-Pierre D.H., Lavoie J.M., Garrel D., et al. Relationship between insulin sensitivity and the triglyceride-HDL-C ratio in overweight and obese postmenopausal women: a MONET study. Appl Physiol Nutr Metab 32 (2007) 1089-1096
70. Graff-Iversen S., Thelle D.S., and Hammar N. Serum lipids, blood pressure and body weight around the age of the menopause. Eur J Cardiovasc Prev Rehabil 15 (2008) 83-88
71. Richter V., Rassoul F., Hentschel B., Kothe K., Krobara M., Unger R., et al. Age-dependence of lipid parameters in the general population and vegetarians. Z Gerontol Geriatr 37 (2004) 207-213
72. Knauff E.A., Westerveld H.E., Goverde A.J., Eijkemans M.J., Valkenburg O., van Santbrink E.J., et al. Lipid profile of women with premature ovarian failure. Menopause 15 (2008) 919-923
73. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. NIH Publication No. 98-4083 (September 1998), NIH, Bethesda
74. Welty F.K., Stuart E., O'Meara M., and Huddleston J. Effect of addition of exercise to therapeutic lifestyle changes diet in enabling women and men with coronary heart disease to reach Adult Treatment Panel III low-density lipoprotein cholesterol goal without lowering high-density lipoprotein cholesterol. Am J Cardiol 89 (2002) 1201-1204
75. Slentz C.A., Houmard J.A., Johnson J.L., Bateman L.A., Tanner C.J., McCartney J.S., et al. Inactivity, exercise training and detraining, and plasma lipoproteins. STRRIDE: a randomized, controlled study of exercise intensity and amount. J Appl Physiol 103 (2007) 432-442
76. Ferrannini E. Physiological and metabolic consequences of obesity. Metabolism 44 (1995) 15-17
77. Yusuf S., Hawken S., Ounpuu S., Tanomsup S., Wangai Jr. P., Razak F., et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 366 (2005) 1640-1649
78. Peverill R.E., Teede H.J., Malan E., Kotsopoulos D., Smolich J.J., and McGrath B.P. Relationship of waist and hip circumference with coagulation and fibrinolysis in postmenopausal women. Clin Sci 113 (2007) 383-391
79. Bogers R.P., Bemelmans W.J., Hoogenveen R.T., Boshuizen H.C., Woodward M., Knekt P., et al., BMI-CHD Collaboration Investigators. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med 167 (2007) 1720-1728
80. Deibert P., König D., Vitolins M.Z., Landmann U., Frey I., Zahradnik H.P., et al. Effect of a weight loss intervention on anthropometric measures and metabolic risk factors in pre- versus postmenopausal women. Nutr J 6 (2007) 31
81. Schmitz K.H., Hannan P.J., Stovitz S.D., Bryan C.J., Warren M., and Jensen M.D. Strength training and adiposity in premenopausal women: strong, healthy, and empowered study. Am J Clin Nutr 86 (2007) 566-572
82. Church T.S., Earnest C.P., Skinner J.S., and Blair S.N. Effects of different doses of physical activity on cardiorespiratory fitness among sedentary, overweight or obese postmenopausal women with elevated blood pressure: a randomized controlled trial. JAMA 297 (2007) 2081-2091
83. ATP III. Final Report. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf. Last accessed January 2, 2009.
84. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Brussels: IDF, 2005. Available at: http://www.idf.org/webdata/docs/metac_syndrome_def.pdf. Last accessed on September 24, 2008.
85. Dørum A., Tonstad S., Liavaag A.H., Michelsen T.M., Hildrum B., and Dahl A.A. Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2). Gynecol Oncol 109 (2008) 377-383
86. Akosah K.O., McHugh V.L., Barnhart S.I., Schaper A.M., Mathiason M.A., Perlock P.A., et al. Carotid ultrasound for risk clarification in young to middle-aged adults undergoing elective coronary angiography. Am J Hypertens 19 (2006) 1256-1261
87. Cabré J.J., Martin F., Costa B., Pinyol J.L., Llor J.L., Ortega Y., et al. Metabolic syndrome as a cardiovascular disease risk factor: patients evaluated in primary care. BMC Public Health 8 (2008) 251
88. Noto D., Barbagallo C.M., Cefalù A.B., Falletta A., Sapienza M., Cavera G., et al. The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean population. Atherosclerosis 197 (2008) 147-153
89. Janssen I., Powell L.H., Crawford S., Lasley B., and Sutton-Tyrrell K. Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation. Arch Intern Med 168 (2008) 1568-1575
90. Martins D., Tareen N., Ogedegbe G., Pan D., and Norris K. The relative risk of cardiovascular death among racial and ethnic minorities with metabolic syndrome: data from the NHANES-II mortality follow-up. J Natl Med Assoc 100 (2008) 565-571
91. Devaraj S., Swarbrick M.M., Singh U., Adams-Huet B., Havel P.J., and Jialal I. CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Am J Clin Pathol 129 (2008) 815-822
92. Chedraui P., Hidalgo L., Chavez D., Morocho N., Alvarado M., and Huc A. Menopausal symptoms and associated risk factors among postmenopausal women screened for the metabolic syndrome. Arch Gynecol Obstet 275 (2007) 161-168
93. Chedraui P., Hidalgo L., Chavez D., Morocho N., Alvarado M., and Huc A. Quality of life among postmenopausal Ecuadorian women participating in a metabolic syndrome screening program. Maturitas 56 (2007) 45-53
94. Barriga J., Castelo-Branco C., Chedraui P., Hidalgo L., and Veas P. Educational and organizational interventions used to improve the knowledge of metabolic syndrome among postmenopausal women. Fertil Steril 90 (2008) 444-446
95. Yang X., Telama R., Hirvensalo M., Mattsson N., Viikari J.S., and Raitakari O.T. The longitudinal effects of physical activity history on metabolic syndrome. Med Sci Sports Exerc 40 (2008) 1424-1431
96. Frank L.L., Sorensen B.E., Yasui Y., Tworoger S.S., Schwartz R.S., Ulrich C.M., et al. Effects of exercise on metabolic risk variables in overweight postmenopausal women: a randomized clinical trial. Obes Res 13 (2005) 615-625
97. Innes K.E., Selfe T.K., and Taylor A.G. Menopause, the metabolic syndrome, and mind-body therapies. Menopause 15 (2008) 1005-1013
98. Rosenson R.S., Wolff D.A., Huskin A.L., Helenowski I.B., and Rademaker A.W. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 30 (2007) 1945-1951
99. Robyn C., Delvoye P., Nokin J., Vekemans M., Badawi M., Pérez-López F.R., et al. Prolactin and human reproduction. In: Pastels J.L., and Robyn C. (Eds). Human prolactin (1973), Excerpta Medica, Amsterdam 167-188
100. Pérez-López F.R., and Robyn C. Studies on human prolactin physiology. Life Sci 15 (1974) 599-616
101. Murphy P.J., and Campbell S.S. Sex hormones, sleep, and core body temperature in older postmenopausal women. Sleep 30 (2007) 1788-1794
102. Kravitz H.M., Zhao X., Bromberger J.T., Gold E.B., Hall M.H., Matthews K.A., et al. Sleep disturbance during the menopausal transition in a multi-ethnic community sample of women. Sleep 31 (2008) 979-990
103. Troxel W.M., Robles T.F., Hall M., and Buysse D.J. Marital quality and the marital bed: examining the covariation between relationship quality and sleep. Sleep Med Rev 11 (2007) 389-404
104. Hall M.H., Muldoon M.F., Jennings J.R., Buysse D.J., Flory J.D., and Manuck S.B. Self-reported sleep duration is associated with the metabolic syndrome in midlife adults. Sleep 31 (2008) 635-643
105. Cappuccio F.P., Stranges S., Kandala N.B., Miller M.A., Taggart F.M., Kumari M., et al. Gender-specific associations of short sleep duration with prevalent and incident hypertension: the Whitehall II Study. Hypertension 50 (2007) 693-700
106. Phillips B., and Mannino D.M. Do insomnia complaints cause hypertension or cardiovascular disease?. J Clin Sleep Med 3 (2007) 489-494
107. Meisinger C., Heier M., Löwel H., Schneider A., and Döring A. Sleep duration and sleep complaints and risk of myocardial infarction in middle-aged men and women from the general population: the MONICA/KORA Augsburg cohort study. Sleep 30 (2007) 1121-1127
108. Suarez E.C. Self-reported symptoms of sleep disturbance and inflammation, coagulation, insulin resistance and psychosocial distress: evidence for gender disparity. Brain Behav Immun 22 (2008) 960-968
109. Tasali E., Leproult R., Ehrmann D.A., and Van Cauter E. Slow-wave sleep and the risk of type 2 diabetes in humans. Proc Natl Acad Sci U S A 105 (2008) 1044-1049
110. Chen J.C., Brunner R.L., Ren H., Wassertheil-Smoller S., Larson J.C., Levine D.W., et al. Sleep duration and risk of ischemic stroke in postmenopausal women. Stroke 39 (2008) 3185-3192
111. King C.R., Knutson K.L., Rathouz P.J., Sidney S., Liu K., and Lauderdale D.S. Short sleep duration and incident coronary artery calcification. JAMA 300 (2008) 2859-2866
112. Gozal D., and Kheirandish-Gozal L. Cardiovascular morbidity in obstructive sleep apnea: oxidative stress, inflammation, and much more. Am J Respir Crit Care Med 177 (2008) 369-375
113. Benjamin J.A., and Lewis K.E. Sleep-disordered breathing and cardiovascular disease. Postgrad Med J 84 (2008) 15-22
114. Winkelman J.W., Shahar E., Sharief I., and Gottlieb D.J. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology 70 (2008) 35-42
115. Oertel W.H., Benes H., Bodenschatz R., Peglau I., Warmuth R., Happe S., et al. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR). Neurology 67 (2006) 1040-1046
116. Van Cauter E., Spiegel K., Tasali E., and Leproult R. Metabolic consequences of sleep and sleep loss. Sleep Med 9 Suppl 1 (2008) S23-S28
117. Ohayon M.M. Severe hot flashes are associated with chronic insomnia. Arch Intern Med 166 (2006) 1262-1268
118. Tworoger S.S., Yasui Y., Vitiello M.V., Schwartz R.S., Ulrich C.M., Aiello E.J., et al. Effects of a Yarlong moderate intensity exercise and stretching intervention on sleep quality in postmenopausal women. Sleep 26 (2003) 830-836
119. Juliá Mollá M.D., García-Sánchez Y., Romeu Sarrió A., and Pérez-López F.R. Cimicifuga racemosa treatment and health related quality of life in postmenopausal women. Gynecol Endocrinol 25 (2009) 21-26
120. Dimpfel W., and Suter A. Sleep improving effects of a single dose administration of a valerian/hops fluid extract-a double blind, randomized, placebo-controlled sleep-EEG study in a parallel design using electrohypnograms. Eur J Med Res 13 (2008) 200-204
121. Kinder L.S., Carnethon M.R., Palaniappan L.P., King A.C., and Fortmann S.P. Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom Med 66 (2004) 316-322
122. Räikkönen K., Matthews K.A., and Kuller L.H. Depressive symptoms and stressful life events predict metabolic syndrome among middle-aged women: a comparison of World Health Organization, Adult Treatment Panel III, and International Diabetes Foundation definitions. Diabetes Care 30 (2007) 872-877
123. Georgiades A., Zucker N., Friedman K.E., Mosunic C.J., Applegate K., Lane J.D., et al. Changes in depressive symptoms and glycemic control in diabetes mellitus. Psychosom Med 69 (2007) 235-241
124. Wassertheil-Smoller S., Shumaker S., Ockene J., Talavera G.A., Greenland P., Cochrane B., et al. Depression and cardiovascular sequelae in postmenopausal women. The Women's Health Initiative (WHI). Arch Intern Med 164 (2004) 289-298
125. Golden S.H., Lazo M., Carnethon M., Bertoni A.G., Schreiner P.J., Diez Roux A.V., et al. Examining a bidirectional association between depressive symptoms and diabetes. JAMA 299 (2008) 2751-2759
126. Penninx B.W., Beekman A.T., Honig A., Deeg D.J., Schoevers R.A., van Eijk J.T., et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 58 (2001) 221-227
127. Chedraui P, Pérez-López FR, Morales B, Hidalgo L. Depressive symptoms among climacteric women are related to menopausal symptom intensity and partner factors. Climacteric. In press.
128. Adams M.R., Kaplan J.R., Clarkson T.B., and Koritnik D.R. Ovariectomy, social status, and atherosclerosis in cynomolgus monkeys. Arteriosclerosis 5 (1985) 192-200
129. Walker S.E., Register T.C., Appt S.E., Adams M.R., Clarkson T.B., Chen H., et al. Plasma lipid-dependent and -independent effects of dietary soy protein and social status on atherogenesis in premenopausal monkeys: implications for postmenopausal atherosclerosis burden. Menopause 15 (2008) 950-957
130. Hanke H., Hanke S., Ickrath O., Lange K., Bruck B., Muck A.O., et al. Estradiol concentrations in premenopausal women with coronary heart disease. Coron Artery Dis 8 (1997) 511-515
131. Krantz D.S., Olson M.B., Francis J.L., Phankao C., Bairey Merz C.N., Sopko G., et al. Anger, hostility, and cardiac symptoms in women with suspected coronary artery disease: the Women's Ischemia Syndrome Evaluation (WISE) Study. J Womens Health (Larchmt) 15 (2006) 1214-1223
132. Harris K.F., Matthews K.A., Sutton-Tyrrell K., and Kuller L.H. Associations between psychological traits and endothelial function in postmenopausal women. Psychosom Med 65 (2003) 402-409
133. Armon G., Shirom A., Shapira I., and Melamed S. On the nature of burnout-insomnia relationships: a prospective study of employed adults. J Psychosom Res 65 (2008) 5-12
134. von Känel R., Bellingrath S., and Kudielka B.M. Association between burnout and circulating levels of pro- and anti-inflammatory cytokines in schoolteachers. J Psychosom Res 65 (2008) 51-59
135. Gómez-Caminero A., Blumentals W.A., Russo L.J., Brown R.R., and Castilla-Puentes R. Does panic disorder increase the risk of coronary heart disease? A cohort study of a national managed care database. Psychosom Med 67 (2005) 688-691
136. Pérez-López F.R. Vitamin D metabolism and cardiovascular risk factors in postmenopausal women. Maturitas 62 (2009) 248-262
137. Wortsman J., Matsuoka L.Y., Chen T.C., Lu Z., and Holick M.F. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 72 (2000) 690-693
138. Pérez-López F.R. Vitamin D and its implications for musculoskeletal health in women: an update. Maturitas 58 (2007) 117-137
139. Rejnmark L., Vestergaard P., Heickendorff L., and Mosekilde L. Plasma 1,25(OH)2D levels decrease in postmenopausal women with hypovitaminosis D. Eur J Endocrinol 158 (2008) 571-576
140. Chiu K.C., Chu A., Go V.L., and Saad M.F. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 79 (2004) 820-825
141. Sandhu M.S., Gibson J.M., Heald A.H., Dunger D.B., and Wareham N.J. Association between insulin-like growth factor-I: insulin-like growth factor-binding protein-1 ratio and metabolic and anthropometric factors in men and women. Cancer Epidemiol Biomarkers Prev 13 (2004) 166-170
142. Forman J.P., Giovannucci E., Holmes M.D., Bischoff-Ferrari H.A., Tworoger S.S., Willett W.C., et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 49 (2007) 1063-1069
143. Hoogendijk W.J., Lips P., Dik M.G., Deeg D.J., Beekman A.T., and Penninx B.W. Depression is associated with decreased 25-hydroxyvitamin D and increased parathyroid hormone levels in older adults. Arch Gen Psychiatry 65 (2008) 508-512
144. Melamed M.L., Michos E.D., Post W., and Astor B. 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 168 (2008) 1629-1637
145. Melamed M.L., Muntner P., Michos E.D., Uribarri J., Weber C., Sharma J., et al. Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease. Results from NHANES 2001 to 2004. Arterioscler Thromb Vasc Biol 28 (2008) 1179-1185
146. Caan B., Neuhouser M., Aragaki A., Lewis C.B., Jackson R., LeBoff M.S., et al. Calcium plus vitamin D supplementation and the risk of postmenopausal weight gain. Arch Intern Med 167 (2007) 893-902
147. De Boer I.H., Tinker L.F., Connelly S., Curb J.D., Howard B.V., Kestenbaum B., et al., Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care 31 (2008) 701-707
148. Gerosa M., De Angelis V., Riboldi P., and Meroni P.L. Rheumatoid arthritis: a female challenge. Women's Health (Lond Engl) 4 (2008) 195-201
149. Kanik K.S., and Wilder R.L. Hormonal alterations in rheumatoid arthritis, including the effects of pregnancy. Rheum Dis Clin North Am 26 (2000) 805-823
150. Cutolo M., Seriolo B., Villaggio B., Pizzorni C., Craviotto C., and Sulli A. Androgens and estrogens modulate the immune and inflammatory responses in rheumatoid arthritis. Ann N Y Acad Sci 966 (2002) 131-142
151. Snow M.H., and Mikuls T.R. Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. Curr Opin Rheumatol 17 (2005) 234-241
152. Rocca W.A., Grossardt B.R., de Andrade M., Malkasian G.D., and Melton III L.J. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 7 (2006) 821-828
153. Rivera C.M., Grossardt B.R., Rhodes D.J., Brown Jr. R.D., Roger V.L., Melton III L.J., et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 16 (2009) 15-23
154. Carr M.C. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 88 (2003) 2404-2411
155. King D.E., Mainous III A.G., and Geesey M.E. Turning back the clock: adopting a healthy lifestyle in middle age. Am J Med 120 (2007) 598-603
156. De Backer G., Ambrosioni E., Borch-Johnsen K., Brotons C., Cifkova R., Dallongeville J., et al. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 8 societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24 (2003) 1601-1610
157. Mosca L., Banka C.L., Benjamin E.J., Berra K., Bushnell C., Dolor R.J., et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 115 (2007) 1481-1501
158. Carels R.A., Darby L.A., Cacciapaglia H.M., and Douglass O.M. Reducing cardiovascular risk factors in postmenopausal women through a lifestyle change intervention. J Womens Health (Larchmt) 13 (2004) 412-426